Farmadosis Accelerates Overseas to Reach 25 Million by 2021

The Spanish company Farmadosis based in Mallorca is forecasting growth of 8.7% in 2021, which is equivalent to reaching a turnover of $30.5 million (€25 million) in the same period. These figures would mean a fourfold increase in the company’s turnover from 2018, as explained by the company.

The biotech company is currently immersed in an international growth plan and plans to expand its presence in Costa Rica. At the same time, it also intends to expand into other countries such as Chile, Mexico, and the United States. The objective of this expansion plan is to work, both directly and indirectly, with customers to manufacture healthcare equipment and drug solutions.

In 2020, Farmadosis took control of Atepharma with the aim of strengthening its presence in the nursing home and social-healthcare sector. This company oversees the pharmaceutical care of 30,000 residents in Spain and will add another 15,000 people this year.

read more about Farmadosis and its plans to expand and fin the most important financial headlines with our companion app Born2Invest.

Farmadosis has developed its own software that facilitates the traceability of medication intake in nursing homes and socio-health centers

Diversifying its market is also an objective for Farmadosis. The biotech company intends to expand its presence in the field of technology and thus not only focus on consumables. In fact, the Balearic company has developed its own software that facilitates the traceability of medication intake in nursing homes and social and healthcare centers.

In this regard, in 2020 the company reached several agreements with foreign companies, such as the Japanese Panasonic and the Chinese Laoken, with the aim of supplying specific dispensing machines in which to include its own software.

On the other hand, the pandemic has not prevented Farmadosis from expanding its staff to 53 employees in 2021. This figure means having increased its staff by 33% over the last two years, a rate that the company claims to be able to accelerate in the coming months.

The Balearic Government has awarded Farmadosis a contract valued at $672,200 (€549,900) for the acquisition of health and protection material against Covid-19

The company, with headquarters in Palma and logistics headquarters in Terrassa (Barcelona), has recently opened a new technological warehouse and another one for health material in Madrid. Farmadosis also expects to close a financing round before the summer. In addition, in the last month, the Balearic Government has awarded Farmadosis a contract valued at $672,200 (€549,900) for the purchase of health and protection material against COVID-19.

__

(Featured image by McRonny via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.